These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7630846)

  • 1. Niacin for lipid disorders. Indications, effectiveness, and safety.
    Brown WV
    Postgrad Med; 1995 Aug; 98(2):185-9, 192-3. PubMed ID: 7630846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinic acid in the treatment of hyperlipidaemia.
    Drexel H
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding niacin formulations.
    Pieper JA
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S308-14. PubMed ID: 12240702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of immediate-release niacin in patients with ischemic cardiopathy. Experience of the Instituto Nacional de Cardiología "Ignacio Chávez"].
    Morato Hernández ML; Ichazo Cerro MS; Alvarado Vega AG; Zamora González J; Cardoso Saldaña GC; Posadas Romero C
    Arch Inst Cardiol Mex; 2000; 70(4):367-76. PubMed ID: 11075282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    Jones PH
    Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    O'Connor PJ; Rush WA; Trence DL
    J Fam Pract; 1997 May; 44(5):462-7. PubMed ID: 9152263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic therapy for the hyperlipidemic patient.
    Hunninghake DB
    Am J Med; 1983 May; 74(5A):19-22. PubMed ID: 6846378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choosing drug therapy for patients with hyperlipidemia.
    Safeer RS; Lacivita CL
    Am Fam Physician; 2000 Jun; 61(11):3371-82. PubMed ID: 10865931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats.
    Bolkent S; Yanardag R; Bolkent S; Döger MM
    Biol Trace Elem Res; 2004 Dec; 101(3):219-29. PubMed ID: 15564652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.